Transgene SA (FR:TNG)
:TNG
Total Valuation
Transgene has a market cap or net worth of €210.91M. The enterprise value is €108.31M.
Market Cap€210.91M
Enterprise Value€108.31M
Share Statistics
Transgene has 274,186,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding274,186,700
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Transgene’s return on equity (ROE) is -0.31 and return on invested capital (ROIC) is -27.43%.
Return on Equity (ROE)-0.31
Return on Assets (ROA)-0.27
Return on Invested Capital (ROIC)-27.43%
Return on Capital Employed (ROCE)-0.32
Revenue Per Employee951.39
Profits Per Employee-260.58K
Employee Count144
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Transgene is ―. Transgene’s PEG ratio is 0.36.
PE Ratio―
PS Ratio282.76
PB Ratio1.14
Price to Fair Value1.14
Price to FCF-3.69
Price to Operating Cash Flow-3.40
PEG Ratio0.36
Income Statement
In the last 12 months, Transgene had revenue of 137.00K and earned -37.52M in profits. Earnings per share was -0.26.
Revenue137.00K
Gross Profit490.00K
Operating Income-41.07M
Pretax Income-44.24M
Net Income-37.52M
EBITDA-39.77M
Earnings Per Share (EPS)-0.26
Cash Flow
In the last 12 months, operating cash flow was -36.74M and capital expenditures -842.00K, giving a free cash flow of -37.58M billion.
Operating Cash Flow-36.74M
Free Cash Flow-37.58M
Free Cash Flow per Share-0.14
Dividends & Yields
Transgene pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.44
52-Week Price Change21.45%
50-Day Moving Average0.81
200-Day Moving Average1.00
Relative Strength Index (RSI)47.68
Average Volume (3m)129.86K
Important Dates
Transgene upcoming earnings date is Apr 29, 2026, During Market Hours (Confirmed).
Last Earnings DateMar 24, 2026
Next Earnings DateApr 29, 2026
Ex-Dividend Date―
Financial Position
Transgene as a current ratio of 9.62, with Debt / Equity ratio of 1.69%
Current Ratio9.62
Quick Ratio9.62
Debt to Market Cap0.01
Net Debt to EBITDA0.12
Interest Coverage Ratio-16.66
Taxes
In the past 12 months, Transgene has paid -6.72M in taxes.
Income Tax-6.72M
Effective Tax Rate0.15
Enterprise Valuation
Transgene EV to EBITDA ratio is -3.37, with an EV/FCF ratio of -3.56.
EV to Sales273.37
EV to EBITDA-3.37
EV to Free Cash Flow-3.56
EV to Operating Cash Flow-3.65
Balance Sheet
Transgene has €111.86M in cash and marketable securities with €2.06M in debt, giving a net cash position of €109.80M billion.
Cash & Marketable Securities€111.86M
Total Debt€2.06M
Net Cash€109.80M
Net Cash Per Share€0.40
Tangible Book Value Per Share€0.84
Margins
Gross margin is 0.00%, with operating margin of -8381.63%, and net profit margin of -7657.96%.
Gross Margin0.00%
Operating Margin-8381.63%
Pretax Margin-9029.39%
Net Profit Margin-7657.96%
EBITDA Margin-8116.33%
EBIT Margin-8381.63%
Analyst Forecast
The average price target for Transgene is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast111.76%
EPS Growth Forecast-22.45%